OTC · CLCS
Cell Source, Inc.
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
Loading market information…
OTC · ZHCLF · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Zenith Capital Corp.’s quoted price sits in the lower half of its reported 52-week range, 99.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.53+$0.06 (+13.97%)
Cell Source, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.45% below the high.
CA$0.31+CA$0.02 (+5.08%)
Telescope Innovations Corp.’s quoted price sits in the lower half of its reported 52-week range, 71.82% below the high.
$0.03$0.00 (0.0%)
Quest PharmaTech Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.23% below the high.
$2.11$0.00 (0.0%)
Propanc Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.35% below the high.
$0.05$0.00 (0.0%)
Gemina Laboratories Ltd.’s quoted price sits in the lower half of its reported 52-week range, 85.46% below the high.
$0.02-$0.01 (-39.39%)
Nymox Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 89.99% below the high.
$0.01$0.00 (0.0%)
Sirona Biochem Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.85% below the high.
$0.12$0.00 (0.0%)
Hadasit Bio-Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 7.69% below the high.
